China Isotope & Radiation Corporation and Bayer agree to introduce Xofigo into China

2020-09-02
|
ChinaMedical

On September 1, China Isotope & Radiation Corporation (CIRC) signed an exclusive distribution agreement with Bayer.


According to the agreement, Bayer will grant CIRC the exclusive right to sell Xofigo® (radium chloride [223Ra] injection) in China.


Xofigo is indicated for the treatment of patients with castration-resistant prostate cancer (CRPC), symptomatic bone metastases and no known visceral metastatic disease.


RELATED ARTICLES

Orthopedic AI company Changmugu closes Series A+ of RMB tens of mlns
2020-09-12
|
PEVC , Medical care

Lu Daopei Medical closes Series B+ exceeding RMB 100 mln
2020-09-11
|
PEVC , Medical care

JD.com reaches strategic cooperation with Tongrentang Health
2020-09-09
|
Medical care , PEVC

Tsimaging closes Pre-A round led by BOHE Angel Fund
2020-09-09
|
PEVC , Medical care , Medical device

Forerunner Medical closes Series B with hundreds of million in RMB
2020-09-08
|
Medical care , PEVC
China SDG